menatetrenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists | 1685 | 863-61-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0.23 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral infarction | 43.40 | 32.63 | 16 | 1056 | 23877 | 63464073 |
| Hepatic function abnormal | 43.19 | 32.63 | 18 | 1054 | 37124 | 63450826 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 78.43 | 32.26 | 31 | 921 | 34906 | 34921073 |
| Cerebral infarction | 40.17 | 32.26 | 18 | 934 | 27437 | 34928542 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Cerebral haemorrhage | 90.52 | 25.11 | 40 | 2182 | 57633 | 79684533 |
| Cerebral infarction | 79.21 | 25.11 | 34 | 2188 | 45642 | 79696524 |
| Hepatic function abnormal | 69.69 | 25.11 | 36 | 2186 | 73071 | 79669095 |
| Platelet count decreased | 45.62 | 25.11 | 40 | 2182 | 194624 | 79547542 |
| Disseminated intravascular coagulation | 41.02 | 25.11 | 20 | 2202 | 35822 | 79706344 |
| Brain herniation | 41.01 | 25.11 | 13 | 2209 | 7450 | 79734716 |
| Pneumonia | 38.54 | 25.11 | 67 | 2155 | 660179 | 79081987 |
| Altered state of consciousness | 34.44 | 25.11 | 19 | 2203 | 43803 | 79698363 |
| Embolic stroke | 32.37 | 25.11 | 11 | 2211 | 7815 | 79734351 |
| Upper respiratory tract inflammation | 30.57 | 25.11 | 9 | 2213 | 4026 | 79738140 |
| Pneumonia aspiration | 29.38 | 25.11 | 20 | 2202 | 66947 | 79675219 |
| Brain oedema | 28.61 | 25.11 | 14 | 2208 | 25249 | 79716917 |
| Thalamus haemorrhage | 27.70 | 25.11 | 7 | 2215 | 1775 | 79740391 |
| Pyrexia | 25.13 | 25.11 | 57 | 2165 | 678652 | 79063514 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M05BX08 | MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Other drugs affecting bone structure and mineralization |
| MeSH PA | D003029 | Coagulants |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D006490 | Hemostatics |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:50646 | antiosteoporotic |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agents |
| CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
| MeSH PA | D000933 | Antifibrinolytic Agents |
| MeSH PA | D018977 | Micronutrients |
| MeSH PA | D014815 | Vitamins |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hemorrhagic disease of the newborn due to vitamin K deficiency | indication | 12546009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-synuclein | Transporter | IC50 | 4.82 | CHEMBL | |||||
| Cruzipain | Enzyme | IC50 | 4.74 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D00100 | KEGG_DRUG |
| C0065936 | UMLSCUI |
| CHEBI:16374 | CHEBI |
| 1L3 | PDB_CHEM_ID |
| CHEMBL259223 | ChEMBL_ID |
| DB12148 | DRUGBANK_ID |
| C030814 | MESH_SUPPLEMENTAL_RECORD_UI |
| 2771 | IUPHAR_LIGAND_ID |
| 3292 | INN_ID |
| 27Y876D139 | UNII |
| 5282367 | PUBCHEM_CID |
| DB14936 | DRUGBANK_ID |
| 29495 | RXNORM |
| 337527 | MMSL |
| 35482 | MMSL |
| 37263 | MMSL |
| d09345 | MMSL |
| 012756 | NDDF |
| 013766 | NDDF |
| 22606007 | SNOMEDCT_US |
| 712684001 | SNOMEDCT_US |
| D024482 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
None